Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Head and Neck Cancer

 

VTX-2337 for Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (7406)
Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN)

Investigator: Laura Chow;   Conditions: Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01334177

Ramucirumab + Docetaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01567163

Ramucirumab + Paclitaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01515306

Postoperative Radiation Therapy +/- Cetuximab for Head and Neck Cancer (RTOG 0920)
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer

Investigator: George Laramore, MD, PhD;   Conditions: Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01311063

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (7797)
A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Investigator: Renato G. Martins, MD, MPH;   Conditions: Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01412229